The recombinant proteins manufacturing services market is projected to reach $7.12B by 2030 at 14% CAGR, driven by protein therapeutics pipelines, pharma outsourcing, and GMP bioprocessing demand.
Read More
The recombinant human GCSF injection market is projected to reach $5.86B by 2030 at 8.6% CAGR, driven by cancer care demand, biosimilar adoption, and long-acting injectables.
Read More
The pyoderma gangrenosum treatment market is projected to reach $2.12B by 2030 at a 12.1% CAGR, driven by biologic therapies, combination drug regimens, advanced wound care, personalized treatments, and expanded clinical monitoring.
Read More
The polycythemia market is projected to reach $6.53B by 2030 at 7.0% CAGR, driven by JAK2-targeted therapies, personalized treatments, and advanced hematocrit monitoring.
Read More
The plant-derived analgesics market is projected to reach $5.06B by 2030 at 8.4% CAGR, driven by natural therapeutics adoption, cannabinoid growth, and advanced botanical pain therapies.
Read More
The penicillin API market is projected to reach $12.34 billion by 2030 at a 5.1% CAGR, driven by rising infections, generic antibiotic expansion, and advanced high-purity manufacturing processes.
Read More
The palmoplantar keratoderma market is projected to reach $1.13 billion by 2030 at a 5.2% CAGR, driven by targeted dermatology drugs, biologics, and advanced genetic diagnostics.
Read More
The neuroendocrine prostate cancer market is projected to reach $1.6 billion by 2030 at an 8.7% CAGR, driven by precision oncology, biomarkers, and targeted therapies.
Read More
Nervous System Active Pharmaceutical Ingredients Market Outlook: Growth and Forecast Highlights 2030
The nervous system API market is projected to reach $334.12 billion by 2030 at a 5.6% CAGR, driven by CNS therapies, neurodegenerative treatments, and high-purity API demand.
Read More
The monogenetic disease therapy market is set to reach $45.58 billion by 2030 at a 10.0% CAGR, driven by gene editing advances and precision genetic treatments.
Read More